Reducing Pre-Commercialization Research Time

This case study documents Roivant's efforts to enhance the efficiency of their commercialization processes for a key Ulcerative Colitis (UC) therapy. Roivant, a global healthcare company, employed a dedicated team of data scientists to develop an advanced data model aimed at delivering accurate and timely commercialization insights. The model faced significant challenges due to the complexities of healthcare data integration, which involved extensive data preparation tasks. To address these issues, Roivant collaborated with Kythera Labs, utilizing their Chronic Conditions Asset to streamline data sourcing and integration, which resulted in faster and more accurate analyses. By replacing their previous model with Kythera’s solutions, Roivant reduced the time required for insights from months to hours, thereby decreasing departmental overhead and supporting the successful commercialization of the UC therapy, with a total commercial potential valued at approximately $7 billion. This transformation illustrates significant advancements in data utilization for healthcare commercialization.